Sort   by:  
 Page size 
UnknownValidity of the CR-POSSUM model in surgery for colorectal cancer in Spain (CCR-CARESS study) and comparison with other models to predict operative mortality.
Not available
S-EPMC5789585 | biostudies-literature
UnknownBrilliant blue G, a P2X7 receptor antagonist, attenuates early phase of renal inflammation, interstitial fibrosis and is associated with renal cell proliferation in ureteral obstruction in rats.
Not available
S-EPMC7260756 | biostudies-literature
UnknownCharacteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Not available
S-EPMC9179309 | biostudies-literature
UnknownGasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.
Not available
S-EPMC9511784 | biostudies-literature
UnknownImmuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Not available
S-EPMC7661209 | biostudies-literature
UnknownPatterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.
Not available
S-EPMC4588395 | biostudies-literature
UnknownOutcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
Not available
S-EPMC10772508 | biostudies-literature
UnknownDepth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Not available
S-EPMC5568033 | biostudies-literature
UnknownBelantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
Not available
S-EPMC10251953 | biostudies-literature
UnknownOne-year mortality after ICU admission due to COVID-19 infection.
Not available
S-EPMC8764887 | biostudies-literature
Sort   by:  
 Page size